Polynucleotides encoding novel PCSK9 variants

Details Polynucleotides encoding novel PCSK9 variants Polynucleotides encoding novel PCSK9 variants

2007-06-28

2009-08-11

Fronda, Christian L (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S183000, C435S252300, C435S320100, C536S023100, C536S023200

Reexamination Certificate

active

07572618

ABSTRACT:
The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

REFERENCES:
patent: 7129338 (2006-10-01), Ota et al.
patent: 7300754 (2007-11-01), Abi Fadel et al.
patent: 2003/0119038 (2003-06-01), Bingham et al.
patent: 2004/0023243 (2004-02-01), Henry et al.
patent: 2004/0038242 (2004-02-01), Edmonds et al.
patent: 2004/0248177 (2004-12-01), Fadel et al.
patent: 2005/0101529 (2005-05-01), Yue et al.
patent: 2006/0068428 (2006-03-01), Vance et al.
patent: 2006/0147945 (2006-07-01), Edmonds et al.
patent: 2006/0223088 (2006-10-01), Rosen et al.
patent: 2006/0223090 (2006-10-01), Rosen et al.
patent: 2007/0015696 (2007-01-01), Rosen et al.
patent: 2007/0037206 (2007-02-01), Rosen et al.
patent: 1 403 282 (2004-03-01), None
patent: 2002017376 (2002-01-01), None
patent: 2002017376 (2002-01-01), None
patent: 2003512840 (2003-04-01), None
patent: 2005130764 (2005-05-01), None
patent: WO01/31007 (2001-05-01), None
patent: WO01/57081 (2001-08-01), None
patent: WO01/98468 (2001-12-01), None
patent: WO02/46383 (2002-06-01), None
patent: WO02/090526 (2002-11-01), None
patent: WO02/012993 (2002-12-01), None
patent: WO02/012994 (2002-12-01), None
patent: WO2004/097047 (2004-11-01), None
patent: WO2007030937 (2007-03-01), None
patent: WO2007128121 (2007-11-01), None
Seidah et al. Int J Biochem Cell Biol. 2008;40(6-7):1111-25. Epub Feb. 8, 2008.
Allard, D. et al., “Novel Mutations of the PCSK9 Gene Cause Variable Phenotype of Autosomal Dominant Hypercholesterolemia”, Human Mutation, Mutation in Brief#854 (2005) Online.
Benjannet, S. et al., “The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A”, The Journal of Biological Chemistry, vol. 281(41), pp. 30561-30571 (2006).
Cameron, J. et al., “Effect of mutations in thePCSK9gene on the cell surface LDL receptors”, Human Molecular Genetics, vol. 15(9), pp. 1551-1558 (2006).
Cohen, Ph.D., J. et al., “Sequence Variations inPCSK9, Low LDL, and Protection against Coronary Heart Disease”, The New England Journal of Medicine, vol. 354(12), pp. 1264-1272 (2006).
Costet, P. et al., “Hepatic PCSK9 Expression is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c”, The Journal of Biological Chemistry, vol. 281(10), pp. 6211-6218 (2006).
Evans, D. et al., “The E670G SNP in thePCSK9gene is associated with polygenic hypercholesterolemia in men but not in women”, MNC Medical Genetics, vol. 7(66), pp. 1-5 (2006).
Holla, {acute over (Ø)}. et al., “Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly”, BMC Cell Biology, vol. 8(9), pp. 1-12 (2007).
Kotowski, I. et al., “A Spectrum ofPCSK9Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol”, The American Journal of Human Genetics, vol. 78, pp. 410-422 (2006).
Leren, TP., “Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia”, Clin Genet, vol. 65, pp. 419-422 (2004).
Naoumova, R. et al., “Severe Hypercholesterolemia in Four British Families with the D374Y Mutation in the PCSK9 Gene Long-Term Follow-Up and Treatment response”, Arterioscler Thromb Basc Biol., vol. 25, pp. 2654-2660 (2005).
Ouguerram, K. et al., “Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations inPCSK9”, Arterioscler Throm Basc Biol., vol. 24, pp. 1448-1453 (2004).
Pisciotta, L. et al., “Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia”, Atherosclerosis, vol. 186, pp. 433-440 (2006).
Shibata, N. et al., “No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients”, Psychiatric Genetics, vol. 15 p. 239 (2005).
Yue, P. et al., “The c.43—44insCTG Variation inPCSK9is Associated with Low Plasma LDL-Cholesterol in a Caucasian Population”, Human Mutation, vol. 27(5), pp. 460-466, (2006).
Abifadel, M. et al., “PCSK9, du gène à la proteéine, Un Nouvel Acteur dans I'homéostasie du cholestérol”, Medicine Sciences, vol. 22, pp. 916-918 (2006).
Abifadel, et al., “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia”, Nature Genetics, vol. 34(2), pp. 154-156 (2003).
Attie, Alan, D., “The Mystery of PCSK9”, Arterioscler. Thromb. Vasc. Biol., vol. 24, pp. 1337-1339 (2004).
Austin, et al., “Risk Factors For Coronary Heart Disease In Adult Female Twins”, Amer. J. Epidemiology, vol. 125(2), pp. 308-318 (1987).
Benjannet, et al., “NARC-1/PCSK9 and Its Natural Mutants”, J. Biol. Chem., vol. 279(47), pp. 48865-48875 (2004).
Berge, et al., “Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy”, Arterioscler. Thromb. Vasc. Biol., vol. 26, pp. 1094-1100 (2006).
Brown, et al., “A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood”, PNAS, vol. 96, pp. 11041-11048 (1999).
Cohen, et al., “Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9”, Nature Genetics, vol. 37(2), pp. 161-165 (2005).
Desai, et al., “Nell1-deficient mice have reduced expression of extracellular matrix proteins causing cranial and vertebral defects”, Human. Molec. Genetics, vol. 15(8), pp. 1329-1341 (2006).
Dubuc, et al., “Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia”, Arterioscler. Thromb. Vasc. Biol., vol. 24, pp. 1454-1459 (2004).
Fredrickson, et al., “Fat Transport in Lipoproteins—An Integrated Approach To Mechanisms And Disorders (Concluded)”, New Eng. J. Medicine, vol. 276(5), pp. 273-281 (1967).
Goldstein, et al., “Familial Hypercholesterolemia: Pathogenesis of a Receptor Disease”, Johns Hopkins Med. J., vol. 143, pp. 8-16 (1978).
Graham, et al., “Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice”, J. Lipid Res., vol. 48, pp. 763-767 (2007).
Hallman, et al., Relation of PCSK9 Mutations to Serum Low-Density Lipoprotein Cholesterol in Childhood and Adulthood (from the Bogalusa Heart Study), Am. J. Cardiol., vol. 100, pp. 69-72 (2007).
Horton, et al., “Molecular biology of PCSK9: its role in LDL metabolism”, TIBS, vol. 32(2), vol. 32(2), pp. 71-77 (2007).
Houghten, et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery”, Nature, vol. 354, pp. 84-86 (1991).
Hunt, et al., “Genetic Localization to Chromosome 1p32 of the Third Locus for Familial Hypercholesterolemia in a Utah Kindred”, Arterioscler. Thromb. Vasc. Biol., vol. 20, pp. 1089-1093 (2000).
Innerarity, et al., “Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding”, PNAS, vol. 84, pp. 6919-6923 (1987).
Khachadurian, Avedis, K., “The Inheritance of Essential Familial Hypercholesterolemia”, American J. Med., vol. 37, pp. 402-407 (1964).
Lagace, et al., “Secreted PCSK9 decreases the number of LDL rece

Affiliated with

Also associated with

Rating

Polynucleotides encoding novel PCSK9 variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polynucleotides encoding novel PCSK9 variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding novel PCSK9 variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134674